Updated:
IMMUTEP Ltd
IMMUTEP Ltd is an Australian public biotech developing LAG-3 immunotherapies, led by CEO Marc Voigt and partnered with Novartis since 2023.
IMMUTEP Ltd
IMMUTEP Ltd was originally incorporated in Sydney in 1987 and has spent over three decades focused on lymphocyte activation gene-3 (LAG-3) biology. The company is led by CEO Marc Voigt and Scientific Founder Frédéric Triebel, who first cloned the LAG-3 gene in 1990. It trades on the Australian Securities Exchange (ASX: IMM) and the Nasdaq (NASDAQ: IMMP) — a structure that sources its deployment capital from equity markets rather than a single-family balance sheet. The firm's central strategy is developing eftilagimod alpha, a soluble LAG-3 protein designed to activate antigen-presenting cells. Its clinical footprint spans several advanced-stage trials, most notably the TACTI-002/003 programs evaluating efti in combination with pembrolizumab (Merck's Keytruda) for first-line non-small cell lung cancer and head and neck squamous cell carcinoma. A pivotal partnership with Novartis, signed in 2023 (per the firm, October 2023), involves a global license for multiple solid tumor indications, generating upfront and milestone payments that fund ongoing R&D. Trial sites concentrate in Europe, Australia, and the United States. As of its latest filings, IMMUTEP remains pre-revenue with an operating model dependent on partnered milestone income and periodic capital raises. Its cash runway is calibrated against Phase II data readouts and the pace of regulatory engagement. Recent operational highlights include the January 2025 disclosure of mature overall survival data from TACTI-003, which reported a 21-month median OS in a PD-L1 all-comer patient population (per the firm, January 2025). Adjacent vehicles or philanthropic arms are not disclosed. IMMUTEP's structural distinction lies in a single-target thesis sustained across four decades. Unlike diversified biotech platforms, the firm's entire pipeline — and by extension its valuation — tethers to LAG-3's biological validation. That narrowness operates as an extreme concentration risk that SHK management has publicly debated, but it also positions IMMUTEP as the sole pure-play LAG-3 asset available to public-market healthcare investors.
General information
Firm type
Asset Manager
Year founded
1987
AUM
Undisclosed
Location
Region
Oceania
Country
Australia
City
Sydney
Corporate office
Sydney, Australia
Principals
Marc Voigt
Chief Executive Officer
Frédéric Triebel
Chief Scientific Officer
Sector focus
Frequently asked questions
How does IMMUTEP generate capital, given it has no revenue?
IMMUTEP is a publicly listed clinical-stage biotech that funds its operations through equity raises on the ASX and Nasdaq, partnered milestone payments — most notably from its 2023 global license deal with Novartis — and Australian government R&D tax incentives. It does not operate from a proprietary balance sheet or endowment and regularly taps public markets to finance its Phase II/III programs.
What is the structural relationship between IMMUTEP and Novartis?
In October 2023, IMMUTEP granted Novartis an exclusive global license to develop and commercialize eftilagimod alpha for multiple solid tumor indications. The agreement triggered an upfront payment and a package of milestone payments tied to regulatory and commercial progress, making Novartis the company's primary strategic partner and a critical validator of the LAG-3 mechanism beyond Bristol-Myers Squibb's relatlimab.
Who controls scientific direction at the company?
CSO and Scientific Founder Frédéric Triebel maintains oversight of the core research program. Triebel first cloned the LAG-3 gene in 1990 and has led the company's immuno-oncology thesis since its founding. CEO Marc Voigt handles corporate strategy, capital formation, and the Novartis partnership.
Is IMMUTEP a single-family office or does it manage third-party capital?
IMMUTEP is neither a family office nor an asset manager — it is an ASX- and Nasdaq-listed biotechnology company that finances its immunotherapy trials through public equity markets and pharmaceutical partnerships. It does not manage discretionary capital for families or institutions.
What does IMMUTEP's pipeline concentration mean for its risk profile?
The entire company is organized around LAG-3 biology, making its valuation binary on clinical data for eftilagimod alpha. Unlike diversified biopharma platforms, failure of the lead asset likely impairs the enterprise. This single-thesis structure draws attention from healthcare specialist funds comfortable with clinical binary risk.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: